[go: up one dir, main page]

AR036331A1 - Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores - Google Patents

Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores

Info

Publication number
AR036331A1
AR036331A1 ARP020101576A ARP020101576A AR036331A1 AR 036331 A1 AR036331 A1 AR 036331A1 AR P020101576 A ARP020101576 A AR P020101576A AR P020101576 A ARP020101576 A AR P020101576A AR 036331 A1 AR036331 A1 AR 036331A1
Authority
AR
Argentina
Prior art keywords
inhibitors
intermediaries
procedure
development
useful compounds
Prior art date
Application number
ARP020101576A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR036331A1 publication Critical patent/AR036331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El compuesto es éster etílico del ácido (2R,4S)-2-etil-4-metoxicarbonilamino-6-trifluormetil-3,4-dihidro-2H-quinolina-1-carboxílico de fórmula (1) útil como intermediario para la síntesis de inhibidores de la proteína de transferencia del éster de colesterilo (CETP). También se dan a conocer los procedimientos para obtener dichos intermediarios e inhibidores.
ARP020101576A 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores AR036331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
AR036331A1 true AR036331A1 (es) 2004-09-01

Family

ID=23103272

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ARP020101576A AR036331A1 (es) 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Country Status (24)

Country Link
US (3) US6689897B2 (es)
EP (2) EP1425270B1 (es)
JP (2) JP3924251B2 (es)
KR (2) KR100591998B1 (es)
CN (3) CN1297541C (es)
AR (3) AR035963A1 (es)
AT (2) ATE321755T1 (es)
AU (1) AU2002253448B2 (es)
BR (2) BR0209291A (es)
CA (2) CA2445693A1 (es)
CZ (2) CZ20032898A3 (es)
DE (2) DE60210265T2 (es)
DK (2) DK1383734T3 (es)
ES (2) ES2256461T3 (es)
HU (2) HUP0304039A3 (es)
IL (2) IL157546A0 (es)
MX (2) MXPA03009936A (es)
PL (2) PL366584A1 (es)
PT (1) PT1425270E (es)
RU (2) RU2259355C2 (es)
TW (1) TWI250974B (es)
WO (2) WO2002088069A2 (es)
YU (2) YU84403A (es)
ZA (2) ZA200306599B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EP1594843B1 (en) 2003-02-18 2013-05-22 Takasago International Corporation METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
CA2515789A1 (en) * 2003-03-17 2004-09-30 Kaneka Corporation Method for producing(r)-3-[4-(trifluoromethyl)phenylamino]-pentanoic acid amide derivative
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
KR20070002085A (ko) * 2004-04-07 2007-01-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
EP1761521A1 (en) * 2004-06-24 2007-03-14 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
CN101146776A (zh) 2005-02-24 2008-03-19 米伦纽姆医药公司 治疗炎性疾病的pgd2受体拮抗剂
BRPI0611838A2 (pt) * 2005-06-20 2012-08-28 Astrazeneca Ab processo para a preparação de um composto
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
PT2697207T (pt) 2011-04-12 2017-02-14 Chong Kun Dang Pharmaceutical Corp Derivados de 3-(2-aril-cicloalcenilmetil)-oxazolidin-2-ona como inibidores da proteína de transferência de ésteres de colesterol (cetp)
KR20190025737A (ko) * 2011-07-08 2019-03-11 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
HRP20171102T1 (hr) 2013-01-31 2017-10-20 Chong Kun Dang Pharmaceutical Corp. Biaril- ili heterociklički biaril-supstituirani spojevi derivata cikloheksena kao inhibitori cetp
EA201600255A1 (ru) * 2013-11-11 2016-09-30 Лонца Лтд. Способ получения цианосоединений, содержащих элемент 13 группы, с использованием кислоты льюиса
PT3180314T (pt) * 2014-08-12 2022-09-02 Newamsterdam Pharma B V Processo para preparar intermediários sintéticos e derivados de tetraidroquinolina
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205037B (es) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
ATE316532T1 (de) 1998-07-10 2006-02-15 Massachusetts Inst Technology Liganden für metalle und metall-katalysiertes verfahren
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
EP1383734B1 (en) 2006-02-01
WO2002088085A2 (en) 2002-11-07
US6689897B2 (en) 2004-02-10
US6600045B2 (en) 2003-07-29
JP3924250B2 (ja) 2007-06-06
AR044706A2 (es) 2005-09-21
YU84303A (sh) 2006-05-25
CZ20032900A3 (cs) 2004-06-16
DE60209004D1 (de) 2006-04-13
HUP0304039A3 (en) 2005-10-28
ZA200306600B (en) 2004-08-25
AU2002253448B2 (en) 2007-07-05
PL366700A1 (en) 2005-02-07
BR0209291A (pt) 2004-07-13
US20030216576A1 (en) 2003-11-20
ATE321755T1 (de) 2006-04-15
CN100357265C (zh) 2007-12-26
ZA200306599B (en) 2004-10-22
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
CN1529696A (zh) 2004-09-15
JP2004527556A (ja) 2004-09-09
EP1383734A2 (en) 2004-01-28
JP3924251B2 (ja) 2007-06-06
HUP0304041A2 (hu) 2004-04-28
YU84403A (sh) 2006-08-17
KR100591998B1 (ko) 2006-06-22
HK1062294A1 (en) 2004-10-29
CN1505609A (zh) 2004-06-16
KR100639745B1 (ko) 2006-10-30
CZ20032898A3 (cs) 2004-07-14
WO2002088069A9 (en) 2003-12-04
HUP0304039A2 (hu) 2004-03-29
EP1425270B1 (en) 2006-03-29
DE60210265T2 (de) 2006-10-12
HU225777B1 (en) 2007-08-28
DK1383734T3 (da) 2006-05-15
DE60209004T2 (de) 2006-09-28
TWI250974B (en) 2006-03-11
ATE316957T1 (de) 2006-02-15
RU2003131870A (ru) 2005-01-27
ES2259080T3 (es) 2006-09-16
WO2002088069A2 (en) 2002-11-07
WO2002088069A3 (en) 2003-02-20
US6706881B2 (en) 2004-03-16
IL157546A0 (en) 2004-03-28
CN1297541C (zh) 2007-01-31
CA2445693A1 (en) 2002-11-07
US20020177716A1 (en) 2002-11-28
WO2002088085A3 (en) 2004-03-25
DE60210265D1 (de) 2006-05-18
CN1680292A (zh) 2005-10-12
CN1267411C (zh) 2006-08-02
MXPA03009936A (es) 2004-01-29
RU2265010C2 (ru) 2005-11-27
JP2004531541A (ja) 2004-10-14
CA2445623A1 (en) 2002-11-07
MXPA03009935A (es) 2004-01-29
IL157544A0 (en) 2004-03-28
DK1425270T3 (da) 2006-07-03
KR20040015200A (ko) 2004-02-18
HUP0304041A3 (en) 2005-08-29
AR035963A1 (es) 2004-07-28
RU2003131871A (ru) 2005-04-10
US20030073843A1 (en) 2003-04-17
PL366584A1 (en) 2005-02-07
PT1425270E (pt) 2006-07-31
EP1425270A2 (en) 2004-06-09
ES2256461T3 (es) 2006-07-16
BR0209238A (pt) 2004-06-15

Similar Documents

Publication Publication Date Title
AR036331A1 (es) Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
CR8530A (es) Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
EA200100451A1 (ru) Замещенные аналоги бензопирана для лечения воспаления
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
ATE359786T1 (de) Camptothecin derivate
GT200000190A (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas-4-carboxiamino-2-sustituidas.
AR034699A1 (es) Procedimiento para la preparacion de moduladores del receptor glucocorticoide no esteroideos y compuestos intermediarios
TR200400857T4 (tr) Yeni galantamın türevleri ve analogları
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
AR016175A1 (es) Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.
MX9304399A (es) Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
PT775117E (pt) Analogos de 2-nitroimidazole fluorinados para detectar celulas de tumor hipoxicas
ES532147A0 (es) 1h-imidazol-1-etanol y esteres derivados del mismo, asi como procedimiento para su obtencion
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
CY1111606T1 (el) Διαδικασια διαχωρισμου για to (r)-(-)-2-yδροξy-2- (2-χλωροφαινυλ) οξικο οξυ
EA199900204A1 (ru) Способы и промежуточные соединения для получения замещенных производных хроманола
ES8300711A1 (es) Un procedimiento para la preparacion de un derivado cis-4,5-disustituidos de imidazolidin-2-ona opticamente activo.
BRPI0409154A (pt) processo para a preparação de 5-(haloacetil)-8-(óxi substituìdo)-(1h)-quinolin-2-onas
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
EA200100213A1 (ru) Способ синтеза производных (1h)-бензо[c]хинолизин-3-онов
ATE416174T1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
BR0110805A (pt) Processo para a preparação de compostos de anilina
BRPI0416678A (pt) pirazolpirimidinas
ATE9225T1 (de) Derivate des 5-hydroxy-tetrahydro-2-furanons.

Legal Events

Date Code Title Description
FB Suspension of granting procedure